FDA 483 - Octapharma Plasma Inc - March 24, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Octapharma Plasma Inc in Baton Rouge, LA, a source plasma center, revealed a significant failure to perform thorough investigations into unexplained discrepancies. The firm consistently failed to identify root causes and implement effective corrective and preventative actions for recurring issues, including high red blood cell loss rates and minor deviation error rates over an extended period. This indicates a systemic weakness in the firm's quality management and deviation investigation processes.
ID · 540d1771-12de-421b-9c08-a17240270d49